Lista de obras - Zachary Hunter - Dominio Público Uruguay

A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia

scientific article published on 29 January 2020

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

artículo científico publicado en 2013

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.

artículo científico publicado en 2017

Associated malignancies in patients with Waldenström's macroglobulinemia and their kin.

artículo científico publicado en 2011

Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

artículo científico publicado en 2011

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.

artículo científico publicado en 2018

Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy

artículo científico publicado en 2009

CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.

artículo científico publicado en 2008

CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia

artículo científico publicado en 2005

CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia.

artículo científico publicado en 2005

CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.

artículo científico publicado en 2017

CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia

artículo científico publicado en 2019

CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells

artículo científico publicado en 2014

CXCR4 in Waldenström's Macroglobulinema: chances and challenges

artículo científico publicado en 2020

CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors

scientific article published on 13 January 2020

CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review

scientific article published on 30 July 2019

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia

artículo científico publicado en 2014

Characterization of familial Waldenstrom's macroglobulinemia

scientific article published on 15 December 2005

Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia

artículo científico publicado en 2008

Clinical responses to sildenafil in Waldenstrom's macroglobulinemia.

artículo científico publicado en 2004

Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling

artículo científico publicado en 2016

Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia

artículo científico publicado en 2015

Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.

artículo científico publicado en 2009

Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia

artículo científico publicado en 2017

Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance

scientific article published on 10 February 2014

Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia

artículo científico publicado en 2018

Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.

artículo científico publicado en 2008

Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.

artículo científico publicado en 2007

Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia

artículo científico publicado en 2009

Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas

scientific article published on 01 January 2020

Extracellular vesicle-mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling

artículo científico publicado en 2018

Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia

scientific article published on 17 October 2012

Future therapeutic options for patients with Waldenström macroglobulinemia

artículo científico publicado en 2016

Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy

artículo científico publicado en 2007

Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia

scientific article published on 27 February 2020

Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.

artículo científico publicado en 2017

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.

artículo científico publicado en 2016

Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia.

artículo científico publicado en 2007

Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia

artículo científico publicado en 2011

Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia

artículo científico publicado en 2016

Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenström's Macroglobulinemia ⬇️

artículo científico publicado el 1 de febrero de 2011

Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia

artículo científico publicado en 2011

Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia.

artículo científico publicado en 2006

Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.

artículo científico publicado en 2017

Ibrutinib in previously treated Waldenström's macroglobulinemia.

artículo científico publicado en 2015

Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome.

artículo científico publicado en 2016

Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity

artículo científico publicado en 2016

IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia.

artículo científico publicado en 2009

Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database.

artículo científico publicado en 2015

Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs

artículo científico publicado en 2008

Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia

artículo científico publicado en 2018

Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.

artículo científico publicado en 2009

Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab

artículo científico publicado en 2011

Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia

artículo científico publicado en 2018

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction ⬇️

artículo científico publicado el 15 de enero de 2013

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

artículo científico publicado en 2012

MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia

scientific article published on 01 August 2015

MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia.

artículo científico publicado en 2016

MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival

artículo científico publicado en 2017

MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia.

scientific article published on 12 March 2014

Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen

artículo científico publicado en 2011

Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling

artículo científico publicado en 2006

Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27

artículo científico publicado en 2011

Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.

artículo científico publicado en 2012

Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.

artículo científico publicado en 2007

Novel agents in the treatment of Waldenström's macroglobulinemia.

artículo científico publicado en 2007

Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.

artículo científico publicado en 2017

Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database

artículo científico publicado en 2014

Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia

artículo científico publicado en 2004

Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib

artículo científico publicado en 2020

Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration

artículo científico publicado en 2013

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia

Prospective clinical trial of ixazomib, dexamethasone and rituximab as primary therapy in Waldenström macroglobulinemia.

artículo científico publicado en 2018

Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).

artículo científico publicado en 2016

Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes

artículo científico publicado en 2016

Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia

artículo científico publicado en 2018

Rituximab intolerance in patients with Waldenström macroglobulinaemia

artículo científico publicado en 2015

SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas

artículo científico publicado en 2020

Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia

artículo científico publicado en 2017

Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia

artículo científico publicado en 2014

Survival outcomes of secondary cancers in patients with Waldenström macroglobulinemia: An analysis of the SEER database.

artículo científico publicado en 2015

Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database.

artículo científico publicado en 2014

Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia

artículo científico publicado en 2016

Targeting NF-kappaB in Waldenstrom macroglobulinemia

artículo científico publicado en 2008

Thalidomide and rituximab in Waldenstrom macroglobulinemia

artículo científico publicado en 2008

The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells

artículo científico publicado en 2015

The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.

artículo científico publicado en 2015

The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia

artículo científico publicado en 2008

The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.

artículo científico publicado en 2014

The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis

artículo científico publicado en 2014

To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenström Macroglobulinaemia.

artículo científico publicado en 2016

Transcriptional repression of plasma cell differentiation is orchestrated by aberrant over-expression of the ETS factor SPIB in Waldenström macroglobulinaemia

artículo científico publicado en 2014

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.

artículo científico publicado en 2016

Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.

artículo científico publicado en 2011

Waldenström Macroglobulinemia

artículo científico publicado en 2014

miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth.

artículo científico publicado en 2016

mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in

article

Lista de obras de Zachary Hunter

A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.

Associated malignancies in patients with Waldenström's macroglobulinemia and their kin.

Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.

Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy

CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.

CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia

CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia.

CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.

CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia

CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells

CXCR4 in Waldenström's Macroglobulinema: chances and challenges

CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors

CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia

Characterization of familial Waldenstrom's macroglobulinemia

Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia

Clinical responses to sildenafil in Waldenstrom's macroglobulinemia.

Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling

Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia

Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.

Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia

Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance

Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia

Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.

Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.

Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia

Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas

Extracellular vesicle-mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling

Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia

Future therapeutic options for patients with Waldenström macroglobulinemia

Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy

Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia

Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.

Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia.

Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia

Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia

Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenström's Macroglobulinemia ⬇️

Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia

Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia.

Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.

Ibrutinib in previously treated Waldenström's macroglobulinemia.

Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome.

Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity

IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia.

Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database.

Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs

Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia

Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.

Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab

Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction ⬇️

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia

MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia.

MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival

MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia.

Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen

Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling

Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27

Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.

Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.

Novel agents in the treatment of Waldenström's macroglobulinemia.

Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.

Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database

Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia

Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib

Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia

Prospective clinical trial of ixazomib, dexamethasone and rituximab as primary therapy in Waldenström macroglobulinemia.

Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).

Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes

Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia

Rituximab intolerance in patients with Waldenström macroglobulinaemia

SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas

Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia